LLY
Lilly(Eli) & Co
$1364.73-3.76%
Setup
①BreakoutBreakout
Buy Zone
$1215-$1275.75
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
77
Recommendation
Watch
Hold①
Quality acceptable but no fresh entry signal.
LLY chart
Loading chart…
ADX
Developing26.4Long Term
Up ↑Intermediate Term
Up ↑Short Term
Range →Overall Quality77
RS Rating
85
relative strength
Fundamentals
79
Strong fund-Q
Volume Demand
68
+91% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Watch
Entry
$1215
Entry Zone
$1215-$1275.75
Stop / Risk
$1117.8
RS Rating
85
Volume confirmed
No
Targets
$1458 / $1518.75
Breakout · IBD Setup
5 ✓ 3 ✗
Entry $1215–$1275.75Stop $1117.8Target $1458 / $1518.75
Market regimeRange
Quality77
RS Rating85
Above 50-MA+12.72%
Above 200-MA+24.26%
VolumeWeak
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
77
MarketRange
Setup①BreakoutBreakout
ConfidenceMedium · 476 trades · 38% win · +0.30R
Fund-Q79 · Strong
StatusHold①
Stock Data
52-Week Range851 – 1450
Price % Chg YTD26.99%
Price % Chg 4wk14.81%
50-Day Avg Vol2.6 Mil
P/E Ratio46.6
Market Cap$1.33T
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)16.25%
Sales % Chg (Qtr)38.61%
EPS Growth 5y27.59%
Sales Growth 5y21.58%
Annual ROE86.09%
Gross Margin83.63%
Operating Margin51.25%
Net Margin31.9%
Debt / Equity1.23
Setup levels
Current price
$1364.73
Pivot
$1215
Distance to buy
-5.9%
52-week range
850.51-1449.68
Trigger evidence
W double-bottom base
broke the middle peak 1215.0 on volume ≥1.4×
Pattern levels: pivot 1215.0
Financial health checks
4/5
Return on equity above 15%
ROE 86.09%
Net margin above 10%
Net margin 31.9%
EPS growing quarter on quarter
EPS q/q 16.25%
Sales growing quarter on quarter
Sales q/q 38.61%
Debt to equity below 1.0
D/E 1.23
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE86.09%
vs sector +63.5%
Net margin31.9%
vs sector +14.2%
Gross margin83.63%
vs sector +16.5%
EPS growth q/q16.25%
vs sector +8.7%
Sales growth q/q38.61%
vs sector +19.9%
Debt / equity1.23
vs sector +0.58
Business quality
79
GradeStrong
EPS rating55
P/E46.6
Market cap$1.33T
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-10-31
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.